Cabozantinib in the Treatment of Neuroendocrine Neoplasms: Insights across Different Tumor Origins

2.

Faivre

S

,

Niccoli

P

,

Castellano

D

,

Valle

JW

,

Hammel

P

,

Raoul

JL

, et al.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

.

Ann Oncol

.

2017

;

28

(

2

):

339

–

43

.

3.

Grillo

F

,

Florio

T

,

Ferraù

F

,

Kara

E

,

Fanciulli

G

,

Faggiano

A

, et al.

Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms

.

Endocr Relat Cancer

.

2018

;

25

(

9

):

R453

–

66

.

4.

Elisei

R

,

Schlumberger

MJ

,

Muller

SP

,

Schoffski

P

,

Brose

MS

,

Shah

MH

, et al.

Cabozantinib in progressive medullary thyroid cancer

.

J Clin Oncol

.

2013

;

31

(

29

):

3639

–

46

.

5.

Cella

CA

,

Minucci

S

,

Spada

F

,

Galdy

S

,

Elgendy

M

,

Ravenda

PS

, et al.

Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside

.

Cancer Treat Rev

.

2015

;

41

(

9

):

754

–

60

.

6.

Murat

CDB

,

Da Rosa

PWL

,

Fortes

MAHZ

,

Corrêa

L

,

Machado

MCC

,

Novak

EM

, et al.

Differential expression of genes encoding proteins of the HGF/MET system in insulinomas

.

Diabetol Metab Syndr

.

2015

;

7

(

1

):

84

–

5

.

7.

Hansel

DE

,

Rahman

A

,

House

M

,

Ashfaq

R

,

Berg

K

,

Yeo

CJ

, et al.

Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms

.

Clin Cancer Res

.

2004

;

10

(

18 Pt 1

):

6152

–

8

.

8.

Krampitz

GW

,

George

BM

,

Willingham

SB

,

Volkmer

JP

,

Weiskopf

K

,

Jahchan

N

, et al.

Correction for Krampitz et al., Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors

.

Proc Natl Acad Sci USA

.

2016

;

113

(

37

):

E5538

.

9.

Reuther

C

,

Heinzle

V

,

Spampatti

M

,

Vlotides

G

,

De Toni

E

,

Spöttl

G

, et al.

Cabozantinib and tivantinib, but not INC280, induce antiproliferative and antimigratory effects in human neuroendocrine tumor cells in vitro: evidence for “Off-Target” effects not mediated by c-met inhibition

.

Neuroendocrinology

.

2016

;

103

(

3–4

):

383

–

401

.

10.

Sennino

B

,

Ishiguro-Oonuma

T

,

Wei

Y

,

Naylor

RM

,

Williamson

CW

,

Bhagwandin

V

, et al.

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

.

Cancer Discov

.

2012

;

2

(

3

):

270

–

87

.

11.

Cella

CA

,

Cazzoli

R

,

Fazio

N

,

De Petro

G

,

Gaudenzi

G

,

Carra

S

, et al.

Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms

.

Endocr Relat Cancer

.

2023

;

30

(

12

):

e230232

.

12.

Chan

JA

,

Faris

JE

,

Murphy

JE

,

Blaszkowsky

LS

,

Kwak

EL

,

McCleary

NJ

, et al.

Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET)

.

J Clin Oncol

.

2017

;

35

(

4_Suppl l

):

228

.

13.

Chan

JA

,

Geyer

S

,

Zemla

T

,

Knopp

MV

,

Behr

S

,

Pulsipher

S

, et al.

Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors

.

N Engl J Med

.

2024

;

16

.

14.

Abstracts Presented at the 13th

.

Annual multidisciplinary neuroendocrine tumor medical virtual symposium of the north American neuroendocrine tumor society, october 2-3, 2020

.

Pancreas

.

2021

;

50

(

3

):

441

–

67

.

15.

Corti

F

,

Brizzi

MP

,

Amoroso

V

,

Giuffrida

D

,

Panzuto

F

,

Campana

D

, et al.

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

.

BMC

.

2023

;

23

(

1

):

908

–

10

.

16.

Study of cabozantinib with Lu-177 in patients with somatostatin receptor 2 positive neuroendocrine tumors

[cited 2024 Oct 19]. Available from: https://clin.larvol.com/trial-detail/NCT05249114

17.

Clemente

O

,

Starita

N

,

Bracigliano

A

,

Cives

M

,

Tatangelo

F

,

Barretta

ML

, et al.

1200P A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial

.

Ann Oncol

.

2023

;

34

:

S708

.

18.

Hernando

J

,

Molina-Cerrillo

J

,

Grande

E

,

Benavent Viñuales

M

,

Garcia-Carbonero

R

,

Teule

A

, et al.

Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): a prospective multi-cohort basket phase II trial (CABATEN/GETNE-T1914)

.

J Clin Oncol

.

2024

;

42

(

16_Suppl l

):

4128

.

19.

Weber

MMM

,

Apostolidis

L

,

Krug

S

,

Rinke

A

,

Gruen

B

,

Michl

P

, et al.

1185MO Activity and safety of avelumab alone or in combination with cabozantinib in patients with advanced high grade neuroendocrine neoplasias (NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter AVENEC and CABOAVENEC trials

.

Ann Oncol

.

2023

;

34

:

S702

.

20.

Record history | ver. 1: 2019-12-11 | NCT04197310 | ClinicalTrials.gov [cited 2024 Oct 24]. Available from: https://clinicaltrials.gov/study/NCT04197310?tab=history&a=1

21.

Borchiellini

D

,

Maillet

D

.

Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient

.

Bull Cancer

.

2022

;

109

(

2S

):

2S4

–

18

.

22.

Rekhtman

N

.

Lung neuroendocrine neoplasms: recent progress and persistent challenges

.

Mod Pathol

.

2022

;

35

(

Suppl 1

):

36

–

50

.

23.

Rindi

G

,

Mete

O

,

Uccella

S

,

Basturk

O

,

La Rosa

S

,

Brosens

LAA

, et al.

Overview of the 2022 WHO classification of neuroendocrine neoplasms

. In:

Kd 33, endocrine pathology

.

Springer US

;

2022

; p.

115

–

54

.

24.

Liccardi

A

,

Colao

A

,

Modica

R

.

Gender differences in lung neuroendocrine tumors: a single-center experience

.

Neuroendocrinology

.

2024

:

1

–

10

.

25.

Granberg

D

,

Wilander

E

,

Öberg

K

.

Expression of tyrosine kinase receptors in lung carcinoids

.

Tumour Biol

.

2006

;

27

(

3

):

153

–

7

.

26.

Ohtaki

Y

,

Kaira

K

,

Yajima

T

,

Erkhem-Ochir

B

,

Kawashima

O

,

Kamiyoshihara

M

, et al.

Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung

.

Thorac Cancer

.

2021

;

12

(

20

):

2666

–

79

.

27.

Ma

PC

,

Jagadeeswaran

R

,

Jagadeesh

S

,

Tretiakova

MS

,

Nallasura

V

,

Fox

EA

, et al.

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer

.

Cancer Res

.

2005

;

65

(

4

):

1479

–

88

.

28.

Song

J

,

Li

M

,

Tretiakova

M

,

Salgia

R

,

Cagle

PT

,

Husain

AN

.

Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung

.

Arch Pathol Lab Med

.

2010

;

134

(

11

):

1702

–

5

.

29.

Dicitore

A

,

Cantone

MC

.

Targeting receptor tyrosine kinases in neuroendocrine neoplasm: what’s going on with lung carcinoids

.

Minerva Endocrinol

.

2022

;

47

(

3

):

261

–

3

.

30.

Lenders

JWM

,

Duh

QY

,

Eisenhofer

G

,

Gimenez-Roqueplo

AP

,

Grebe

SKG

,

Murad

MH

, et al.

Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline

.

J Clin Endocrinol Metab

.

2014

;

99

(

6

):

1915

–

42

.

31.

Nölting

S

,

Bechmann

N

,

Taieb

D

,

Beuschlein

F

,

Fassnacht

M

,

Kroiss

M

, et al.

Personalized management of pheochromocytoma and paraganglioma

.

Endocr Rev

.

2022

;

43

(

2

):

199

–

239

.

32.

Dahia

PLM

.

Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity

.

Nat Rev Cancer

.

2014

;

14

(

2

):

108

–

19

.

33.

Papathomas

TG

,

Suurd

DPD

,

Pacak

K

,

Tischler

AS

,

Vriens

MR

,

Lam

AK

, et al.

What have we learned from molecular biology of paragangliomas and pheochromocytomas

.

Endocr Pathol

.

2021

;

32

(

1

):

134

–

53

.

34.

Toledo

R

,

Jimenez

C

.

Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors

.

F1000Res

.

2018

;

7

:

F1000 Faculty Rev-1148

.

35.

Jimenez

C

,

Fazeli

S

,

Román-Gonzalez

A

.

Antiangiogenic therapies for pheochromocytoma and paraganglioma

.

Endocr Relat Cancer

.

2020

;

27

(

7

):

R239

–

54

.

36.

Wang

K

,

Schütze

I

,

Gulde

S

,

Bechmann

N

,

Richter

S

,

Helm

J

, et al.

Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures

.

Endocr Relat Cancer

.

2022

;

29

(

6

):

285

–

306

.

37.

Carafone

L

,

Victor

A

,

Harbuz-Miller

I

.

A SDHB variant of unknown significance in a patient with a cardiac functional paraganglioma

.

JCEM Case Rep

.

2023

;

1

(

4

):

luad093

.

38.

Ho

WJ

,

Zhu

Q

,

Durham

J

,

Popovic

A

,

Xavier

S

,

Leatherman

J

, et al.

Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity

.

Nat Cancer

.

2021

;

2

(

9

):

891

–

903

.

39.

Lee

CH

,

Voss

MH

,

Carlo

MI

,

Chen

YB

,

Zucker

M

,

Knezevic

A

, et al.

Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates

.

J Clin Oncol

.

2022

;

40

(

21

):

2333

–

41

.

40.

Motzer

RJ

,

Powles

T

,

Burotto

M

,

Escudier

B

,

Bourlon

MT

,

Shah

AY

, et al.

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

.

Lancet Oncol

.

2022

;

23

(

7

):

888

–

98

.

41.

Economides

MP

,

Shah

AY

,

Jimenez

C

,

Habra

MA

,

Desai

M

,

Campbell

MT

.

A durable response with the combination of nivolumab and cabozantinib in a patient with metastatic paraganglioma: a case report and review of the current literature

.

Front Endocrinol

.

2020

;

11

:

594264

.

42.

Jimenez

C

,

Habra

MA

,

Campbell

MT

,

Tamsen

G

,

Cruz-Goldberg

D

,

Long

J

, et al.

Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial

.

Lancet Oncol

.

2024

;

25

(

5

):

658

–

67

.

43.

Grande

E

,

Benavent Viñuales

M

,

Molina-Cerrillo

J

,

Teule

A

,

Jimenez-Fonseca

P

,

Carmona-Bayonas

A

, et al.

Cabozantinib plus atezolizumab in locally advanced/metastatic adrenocortical carcinoma: results from a multi-cohort basket phase II trial, CABATEN/GETNE-T1914

.

J Clin Oncol

.

2024

;

42

(

4_Suppl l

):

1

.

44.

No Study Results Posted

.

Effect of cabozantinib S-malate or lenvatinib mesylate on weight and body composition in patients with metastatic endocrine cancer

.

ClinicalTrials.gov

[cited 2024 Oct 24]. Available from: https://www.clinicaltrials.gov/study/NCT02592356?tab=results

45.

Bhatia

S

,

Storer

BE

,

Iyer

JG

,

Moshiri

A

,

Parvathaneni

U

,

Byrd

D

, et al.

Adjuvant radiation therapy and chemotherapy in merkel cell carcinoma: survival analyses of 6908 cases from the national cancer data base

.

J Natl Cancer Inst

.

2016

;

108

(

9

):

djw042

.

46.

Fojnica

A

,

Ljuca

K

,

Akhtar

S

,

Gatalica

Z

,

Vranic

S

.

An updated review of the biomarkers of response to immune checkpoint inhibitors in merkel cell carcinoma: merkel cell carcinoma and immunotherapy

.

Cancers

.

2023

;

15

(

20

):

5084

.

47.

Schmults

CD

,

Blitzblau

R

,

Aasi

SZ

,

Alam

M

,

Amini

A

,

Bibee

K

, et al.

NCCN Guidelines® insights: merkel cell carcinoma, version 1.2024

.

J Natl Compr Canc Netw

.

2024

;

22

(

1D

):

e240002

.

48.

Haanen

J

,

Obeid

M

,

Spain

L

,

Carbonnel

F

,

Wang

Y

,

Robert

C

, et al.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

.

Ann Oncol

.

2022

;

33

(

12

):

1217

–

38

.

49.

Gide

TN

,

Wilmott

JS

,

Scolyer

RA

,

Long

GV

.

Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma

.

Clin Cancer Res

.

2018

;

24

(

6

):

1260

–

70

.

50.

Yakes

FM

,

Chen

J

,

Tan

J

,

Yamaguchi

K

,

Shi

Y

,

Yu

P

, et al.

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

.

Mol Cancer Ther

.

2011

;

10

(

12

):

2298

–

308

.

51.

Kukko

H

,

Koljonen

V

,

Lassus

P

,

Tukiainen

E

,

Haglund

C

,

Bohling

T

.

Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma

.

Anticancer Res

.

2007

;

27

(

4C

):

2587

–

9

.

52.

Brunner

M

,

Thurnher

D

,

Pammer

J

,

Geleff

S

,

Heiduschka

G

,

Reinisch

CM

, et al.

Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, her-2/neu, mcl-1 and bmi-1 in merkel cell carcinoma

.

Mod Pathol

.

2008

;

21

(

7

):

876

–

84

.

53.

Starrett

GJ

,

Marcelus

C

,

Cantalupo

PG

,

Katz

JP

,

Cheng

J

,

Akagi

K

, et al.

Merkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in virus-associated merkel cell carcinoma

.

mBio

.

2017

;

8

(

1

):

e02079-16

.

54.

Karpinski

P

,

Rosales

I

,

Laczmanski

L

,

Kowalik

A

,

Wenson

S

,

Hoang

MP

.

Expression of genes associated with epithelial-mesenchymal transition in merkel cell polyomavirus-negative merkel cell carcinoma

.

Lab Invest

.

2023

;

103

(

8

):

100177

.

55.

Dong

HY

,

Liu

W

,

Cohen

P

,

Mahle

CE

,

Zhang

W

.

B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas

.

Am J Surg Pathol

.

2005

;

29

(

5

):

687

–

92

.

56.

Tarabadkar

ES

,

Thomas

H

,

Blom

A

,

Parvathaneni

U

,

Olencki

T

,

Nghiem

P

, et al.

Clinical benefit from tyrosine kinase inhibitors in metastatic merkel cell carcinoma: a case series of 5 patients

.

Am J Case Rep

.

2018

;

19

:

505

–

11

.

57.

Rabinowits

G

,

Lezcano

C

,

Catalano

PJ

,

McHugh

P

,

Becker

H

,

Reilly

MM

, et al.

Cabozantinib in patients with advanced merkel cell carcinoma

.

Oncologist

.

2018

;

23

(

7

):

814

–

21

.

58.

Zago

E

,

Galluzzo

A

,

Pradella

S

,

Antonuzzo

L

,

Maggi

M

,

Petrone

L

, et al.

Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature

.

Endocrine

.

2024

;

83

(

1

):

26

–

40

.

59.

Matrood

S

,

Apostolidis

L

,

Schrader

J

,

Krug

S

,

Lahner

H

,

Ramaswamy

A

, et al.

Multicenter analysis of presacral neuroendocrine neoplasms—clinicopathological characterization and treatment outcomes of a rare disease

.

Front Endocrinol

.

2021

;

12

(

12

):

709256

.

60.

Veleno

M

,

Giampietro

A

,

Raia

S

,

Menotti

S

,

Tartaglione

T

,

Gaudino

S

, et al.

Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients

.

Minerva Endocrinol

.

2024

;

49

(

3

):

269

–

82

.

61.

Asioli

S

,

Guaraldi

F

,

Zoli

M

,

Mazzatenta

D

,

Villa

C

.

How to standardize the diagnostic approach to pituitary neuroendocrine tumors

.

Minerva Endocrinol

.

2024

;

49

(

3

):

283

–

92

.

62.

DE Alcubierre

D

,

Carretti

AL

,

Ducray

F

,

Jouanneau

E

,

Raverot

G

,

Ilie

MD

.

Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide

.

Minerva Endocrinol

.

2024

;

49

(

3

):

321

–

34

.

63.

Marques

P

,

Barry

S

,

Carlsen

E

,

Collier

D

,

Ronaldson

A

,

Dorward

N

, et al.

The role of the tumour microenvironment in the angiogenesis of pituitary tumours

.

Endocrine

.

2020

;

70

(

3

):

593

–

606

.

64.

Zhou

J

,

Hu

Y

,

Zhu

W

,

Nie

C

,

Zhao

W

,

Faje

AT

, et al.

Sprouting angiogenesis in human pituitary adenomas

.

Front Oncol

.

2022

;

12

(

April

):

875219

–

8

.

65.

Klöppel

G

.

Neuroendocrine neoplasms: dichotomy, origin and classifications

.

Visc Med

.

2017

;

33

(

5

):

324

–

30

.

66.

Marker

PC

,

Donjacour

AA

,

Dahiya

R

,

Cunha

GR

.

Hormonal, cellular, and molecular control of prostatic development

.

Dev Biol

.

2003

;

253

(

2

):

165

–

74

.

67.

Beltran

H

,

Prandi

D

,

Mosquera

JM

,

Benelli

M

,

Puca

L

,

Cyrta

J

, et al.

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

.

Nat Med

.

2016

;

22

(

3

):

298

–

305

.

68.

Kaarijärvi

R

,

Kaljunen

H

,

Nappi

L

,

Fazli

L

,

Kung

SHY

,

Hartikainen

JM

, et al.

DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2

.

Commun Biol

.

2024

;

7

(

1

):

108

.

69.

Surintrspanont

J

,

Zhou

M

.

Prostate pathology: what is new in the 2022 WHO classification of urinary and male genital tumors

.

Pathologica

.

2022

;

115

(

1

):

41

–

56

.

70.

Fujimoto

N

,

Tsubonuma

Y

,

Nagata

Y

,

Minato

A

,

Tomisaki

I

,

Harada

K

, et al.

Second-line systemic therapy for highly aggressive neuroendocrine prostate cancer

.

Anticancer Res

.

2023

;

43

(

9

):

3841

–

7

.

71.

Drake

JM

,

Graham

NA

,

Lee

JK

,

Stoyanova

T

,

Faltermeier

CM

,

Sud

S

, et al.

Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets

.

Proc Natl Acad Sci USA

.

2013

;

110

(

49

):

E4762

–

9

.

72.

Zamora

I

,

Freeman

MR

,

Encío

IJ

,

Rotinen

M

.

Targeting key players of neuroendocrine differentiation in prostate cancer

.

Int J Mol Sci

.

2023

;

24

(

18

):

13673

.

73.

Guo

CC

,

Czerniak

B

.

Updates of prostate cancer from the 2022 world health organization classification of the urinary and male genital tumors

.

J Clin Transl Pathol

.

2023

;

3

(

1

):

26

–

34

.

74.

Santoni

M

,

Conti

A

,

Burattini

L

,

Berardi

R

,

Scarpelli

M

,

Cheng

L

, et al.

Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives

.

Biochim Biophys Acta

.

2014

;

1846

(

2

):

630

–

7

.

75.

Franceschini

GM

,

Quaini

O

,

Mizuno

K

,

Orlando

F

,

Ciani

Y

,

Ku

S-Y

, et al.

Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation

.

Cancer Discov

.

2024

;

14

(

3

):

424

–

45

.

76.

Zhang

C

,

Qian

J

,

Wu

Y

,

Zhu

Z

,

Yu

W

,

Gong

Y

, et al.

Identification of novel diagnosis biomarkers for therapy-related neuroendocrine prostate cancer

.

Pathol Oncol Res

.

2021

;

27

:

1609968

.

77.

Smith

DC

,

Smith

MR

,

Sweeney

C

,

Elfiky

AA

,

Logothetis

C

,

Corn

PG

, et al.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

.

J Clin Oncol

.

2013

;

31

(

4

):

412

–

9

.

78.

Labrecque

MP

,

Brown

LG

,

Coleman

IM

,

Nguyen

HM

,

Lin

DW

,

Corey

E

, et al.

Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature

.

PLoS One

.

2021

;

16

:

e0245602

.

79.

Smith

M

,

De Bono

J

,

Sternberg

C

,

Le Moulec

S

,

Oudard

S

,

De Giorgi

U

, et al.

Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1

.

J Clin Oncol

.

2016

;

34

(

25

):

3005

–

13

.

80.

Basch

EM

,

Scholz

M

,

de Bono

JS

,

Vogelzang

N

,

de Souza

P

,

Marx

G

, et al.

Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: a randomized phase 3 trial with a primary pain endpoint

.

Eur Urol

.

2019

;

75

(

6

):

929

–

37

.

81.

Sonpavde

GP

,

Pond

GR

,

Fizazi

K

,

de Bono

JS

,

Basch

EM

,

Scher

HI

, et al.

Cabozantinib for progressive metastatic castration-resistant prostate cancer following docetaxel: combined analysis of two phase 3 trials

.

Eur Urol Oncol

.

2020

;

3

(

4

):

540

–

3

.

82.

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

.

ClinicalTrials.gov

[cited 2024 Oct 24]. Available from: https://clinicaltrials.gov/study/NCT04631744

83.

Agarwal

N

,

Azad

A

,

Carles

J

,

Chowdhury

S

,

Mcgregor

B

,

Merseburger

AS

, et al.

A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer

.

Futur Oncol

.

2022

;

18

(

10

):

1185

–

98

.

84.

Agarwal

N

,

Azad

A

,

Carles

J

,

Matsubara

N

,

Oudard

S

,

Saad

F

, et al.

CONTACT-02: phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

.

J Clin Oncol

.

2024

;

42

(

4_Suppl l

):

18

.

85.

Annex 1 summary of product characteristics

[cited 2024 Oct 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/cabometyx-epar-product-information_en.pdf

86.

Modlin

IM

,

Lye

KD

,

Kidd

M

.

A 5-decade analysis of 13,715 carcinoid tumors

.

Cancer

.

2003

;

97

(

4

):

934

–

59

.

87.

Powles

T

,

Burotto

M

,

Escudier

B

,

Apolo

AB

,

Bourlon

MT

,

Shah

AY

, et al.

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

.

ESMO Open

.

2024

;

9

(

5

):

102994

.

88.

Zanger

UM

,

Schwab

M

.

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation

.

Pharmacol Ther

.

2013

;

138

(

1

):

103

–

41

.

89.

Garcia-Torralba

E

,

Spada

F

,

Lim

KHJ

,

Jacobs

T

,

Barriuso

J

,

Mansoor

W

, et al.

Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: a systematic review and meta-analysis

.

Cancer Treat Rev

.

2021

;

94

:

102168

.

90.

Preissner

SC

,

Hoffmann

MF

,

Preissner

R

,

Dunkel

M

,

Gewiess

A

,

Preissner

S

.

Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy

.

PLoS One

.

2013

;

8

(

12

):

e82562

.

91.

Lin

QM

,

Li

YH

,

Lu

XR

,

Wang

R

,

Pang

NH

,

Xu

RA

, et al.

Characterization of genetic variation in CYP3A4 on the metabolism of cabozantinib in vitro

.

Chem Res Toxicol

.

2019

;

32

(

8

):

1583

–

90

.

92.

García-Donas

J

,

Beuselinck

B

,

Inglada-Pérez

L

,

Graña

O

,

Schöffski

P

,

Wozniak

A

, et al.

Deep sequencing reveals microRNAs predictive of antiangiogenic drug response

.

JCI Insight

.

2016

;

1

(

10

):

e86051

.

93.

Mukry

SN

,

Shahni

A

,

Zaidi

U

,

Shamsi

TS

.

Cytochromes P450 and glutathione S-transferases polymorphisms: can they predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia

.

Blood

.

2019

;

134

(

Suppl ment_1

):

5920

.

94.

Diekstra

MHM

,

Klümpen

HJ

,

Lolkema

MPJK

,

Yu

H

,

Kloth

JSL

,

Gelderblom

H

, et al.

Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662

.

Clin Pharmacol Ther

.

2014

;

96

(

1

):

81

–

9

.